Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 97

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 97
---
 the holders of any such patents may be able to block our ability to commercialize
the product candidate unless we were to obtain a license under the applicable patents, or until such patents expire or they are finally
determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to
cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our
ability to develop and commercialize the product candidate unless we were to obtain a license or until such patent expires or is finally
determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms
or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability
to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the
breadth or strength of protection provided by our patents is threatened, it could dissuade companies from collaborating with us to license,
develop or commercialize current or future product candidates.

<div align='center'>49</div>

Parties making claims against
us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize
our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be
a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may
have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses
from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary
expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable
terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our
research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates